Rigel Pharmaceuticals Inc., a drugmaker with no products on the market, fell to its lowest value in four years after its experimental rheumatoid arthritis medicine being developed with AstraZeneca Plc showed mixed results in a trial.
http://washpost.bloomberg.com/Story?docId=1376-MKS7NI6S972A01-4UMCG8UOBJF26SERRDOJ0N5IEH
http://washpost.bloomberg.com/Story?docId=1376-MKS7NI6S972A01-4UMCG8UOBJF26SERRDOJ0N5IEH
No comments:
Post a Comment